CONMED’s (CNMD) Neutral Rating Reiterated at Piper Sandler

Piper Sandler restated their neutral rating on shares of CONMED (NYSE:CNMD) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $45.00 price objective on the stock, up from their prior price objective of $39.00.

A number of other equities research analysts also recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Wall Street Zen raised shares of CONMED from a “hold” rating to a “buy” rating in a research note on Monday, July 20th. BMO Capital Markets began coverage on shares of CONMED in a report on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 price target on the stock. Weiss Ratings restated a “sell (d)” rating on shares of CONMED in a research report on Thursday, June 4th. Finally, Zacks Research downgraded shares of CONMED from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $41.40.

CONMED Price Performance

Shares of NYSE CNMD opened at $46.38 on Thursday. The firm has a market capitalization of $1.39 billion, a P/E ratio of 25.07, a P/E/G ratio of 3.30 and a beta of 0.93. The company has a quick ratio of 1.04, a current ratio of 1.48 and a debt-to-equity ratio of 0.63. The stock’s 50-day simple moving average is $37.27 and its two-hundred day simple moving average is $38.48. CONMED has a twelve month low of $31.44 and a twelve month high of $56.63.

CONMED (NYSE:CNMD) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.27. CONMED had a return on equity of 14.31% and a net margin of 4.12%.The firm had revenue of $343.49 million during the quarter, compared to the consensus estimate of $337.60 million. During the same quarter last year, the company posted $1.15 EPS. The company’s revenue for the quarter was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. As a group, equities analysts anticipate that CONMED will post 4.54 EPS for the current fiscal year.

Hedge Funds Weigh In On CONMED

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its stake in CONMED by 19.9% in the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock worth $857,000 after buying an additional 2,357 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock worth $1,108,000 after acquiring an additional 800 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of CONMED by 5.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock worth $4,993,000 after acquiring an additional 4,565 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of CONMED by 34.6% in the 1st quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock valued at $1,359,000 after purchasing an additional 5,780 shares in the last quarter. Finally, Creative Planning purchased a new stake in shares of CONMED in the 2nd quarter valued at $310,000.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q2 results exceeded expectations. CONMED reported adjusted EPS of $1.38, above the $1.10 consensus estimate and up from $1.15 a year earlier. Revenue reached $343.5 million, surpassing the $337.6 million forecast. CONMED Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised and reaffirmed an above-consensus outlook. CONMED forecast 2026 adjusted EPS of $4.48 to $4.60, compared with analyst expectations near $4.37, while targeting 5% to 6% organic growth. Gross-margin expansion and solid international sales also supported the improved outlook. CONMED 2026 Guidance
• Positive Sentiment: Analysts increased price targets. Wells Fargo raised its target to $46 from $39, and Piper Sandler lifted its target to $45 from $39, reflecting greater confidence following the quarterly performance. Analyst Price Target Changes
• Neutral Sentiment: Management’s earnings presentation and call highlighted the quarter’s operating performance and 2026 growth priorities. The materials provide additional detail on the earnings beat, margins and guidance but do not indicate a major change to the company’s longer-term strategy. CONMED 2026 Q2 Earnings Presentation
• Negative Sentiment: Valuation and limited analyst upside may be weighing on the stock. Piper Sandler maintained a Neutral rating with a $45 target, while Wells Fargo kept an Equal Weight rating at $46—both below or near the recent trading level. Revenue growth was also modest at approximately 0.3% year over year, despite the earnings beat.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.